

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MSB | Sydney | AUD | Delayed | |
MESO | NASDAQ | USD | Real-time | |
MEOBF | OTC Markets | USD | Delayed |
Mesoblast Limited is an Australia-based company that is engaged in the development of regenerative medicine products. The Company’s primary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It has applied its mesenchymal lineage cell technology platform to the allogeneic cellular medicines portfolio in the industry. Its technology addresses multiple inflammatory conditions with unmet medical needs. The Company’s portfolio of Phase III product candidates comprises remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD), as well as for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, Revascor for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s subsidiaries include Mesoblast, Inc., Mesoblast International Sarl, Mesoblast Australia Pty Ltd, Mesoblast UK Ltd and BeiCell Ltd.
Name | Age | Since | Title |
---|---|---|---|
Joseph R. Swedish | 69 | 2018 | Independent Non-Executive Chairman |
William A. M. Burns | 72 | 2014 | Independent Non-Executive Vice Chairman |
Silviu Itescu | 64 | 2004 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director |
Stephen Graves | - | - | Member of Scientific Advisory Board |
Joseph M. Lane | - | - | Member of Scientific Advisory Board |
Richard E. Gilbert | - | - | Member of Scientific Advisory Board |
Michael R. Spooner | 65 | 2004 | Independent Non-Executive Director |
Robert M. Graham | - | - | Member of Scientific Advisory Board |
Henry Krum | - | - | Member of Scientific Advisory Board |
Philip James Facchina | 60 | 2021 | Independent Non-Executive Director |
Jane Catherine Bell | - | 2022 | Independent Non-Executive Director |
Philip R. Krause | - | 2022 | Independent Non Executive Director |
Eric A. Rose | 71 | 2013 | Chief Medical Officer & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review